SDH-IN-27 (Compound Q18) is a succinate dehydrogenase inhibitor (SDHI) (IC50: 9.7 mg/L) . SDH-IN-27 induces mycelial morphology changes and lipid peroxidation, and exhibits antifungal activity against C. camelliae (EC50: 6.0 mg/L) . SDH-IN-27 is an ergosterol biosynthesis inhibitor (EBI) that binds to the active site of CYP51, ultimately leading to cell death of pathogenic fungi[1].
